Left Ventricular Dysfunction News Today

Press release - InsightAce Analytic Pvt.Ltd - Left Appendage Occlusion Device Market Closing the Gap on Stroke Risk: The Left Atrial Appendage Occlusion Device - published on openPR.com

A randomized trial evaluating vitamin K therapy with aspirin or placebo with a left ventricular assist device shows avoiding aspirin reduced bleeding without increasing thrombotic risk.

An early demonstration of the novel artificial intelligence algorithm shows promise to estimate left ventricular ejection fraction without further invasive procedures, but not at the extremes of LVEF.

Beta-blocker treatment beyond 1 year after MI for patients without heart failure or left ventricular systolic dysfunction was not associated with improved cardiovascular outcomes in a new analysis.

Is myocardial viability testing for guiding PCI decisions currently used in the best way? A secondary analysis from the main trial suggests not.

White adults were twice as likely as Black adults to receive a ventricular assist device or heart transplant.

A post-hoc analysis of the PARADISE-MI trial suggests relevant benefits are being missed in current trial design.

The latest recall for the companys HeartWare HVAD System involves defective batteries that could unexpectedly fail due to an electrical fault.

Monitoring of neutrophil-to-lymphocyte ratio could potentially help risk-stratify women on anthracycline chemotherapy for associated left-ventricular dysfunction, a prospective study suggests.

The novel agent most benefited those with low systolic BP, often excluded from major HF trials, but didnt help outcomes when baseline pressures were higher, post hoc analysis of GALACTIC-HF suggests.